Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$110.0M
23M shares
52-week range
$3.71 – $7.75
24% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
www.coyatherapeutics.comNo one on the platform currently holds COYA.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 103,964 | $409.6K |
No one on the platform has traded COYA yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$COYA Hard to keep a good secret...$XBI $BMY https://www.cbsnews.com/philadelphia/video/promising-research-for-als-treatment-underway-at-temple-health-in-philadelphia/
View on StockTwits ↗$COYA So over the last 4 months I did the Due diligence $COYA's VWAP has been higher thsn the close 70% of the time. I dont believe in coincidences....Draw your own conclusions.
View on StockTwits ↗$COYA Yesterday close $4.69 VWAP $4.75...Today close $4.67 VWAP $4.75 SKUNK IN WOOD PILE LAST 40 MINUTES..I have seen this often with COYA. I have my thoughts but will refrain.
View on StockTwits ↗$COYA Nice to see why a leading expert says this trial is different for ALS.
View on StockTwits ↗$COYA He failed to mention that Phase 2 will very likely be sufficient to seek approval, and there will be no need to go through Phase 3.
View on StockTwits ↗$COYA Nice shout out in this interview... https://www.youtube.com/watch?v=0Ck7SR_4mhk&t=3s
View on StockTwits ↗$COYA There is a new audio Interview of Dr. Arun Swaminathan Ph.D., CEO of Coya Therapeutics. Inc. (COYA) @CoyaTx A clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders. Listen at The Wall Street Resource https://thewallstreetresource.com/webcasts/
View on StockTwits ↗$COYA Nice interview. https://thewallstreetresource.com/webcasts/
View on StockTwits ↗$COYA shared its June-30, 2026 quarter results in a press release.
View on StockTwits ↗$COYA Bought a few more as enrollment likely complete Sept 23rd to Oct 15th area in my opinion. Dynamic will change upon that being completed anticipate binary bets being made. Typically gains traction upon this development. After completion of the enrollment one woukd think our FTD trial will start the 50 patients and the 7m per quarter shoukd be about 3.5m approx in my opinion.
View on StockTwits ↗@microcapspeculator Biogen got shot down for their ptimary endpoint in 2021 and took 18 months and in 2023 Biogen was approved for tofersen on their nfl secondary endpoint... $COYA actually benefiited from Biogen's work..We have expanded 2 additional biomarkers with HNE/LDP which show predictive survival which is tied to our orimary endpoint ALSFRS...Our trial design is superior..we treat 95% sporadic and we have the remaining 5% genetic mutation rhat biogen has. In April of 2027 with our readout and I believe it will show we our flawless a fit would be biogen as they do not treat sporadic which we do 95%.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.